What is your approach to using beta-blockers in patients with acute myocardial infarction with preserved LV ejection fraction who undergo early coronary angiography in light of the REDUCE-AMI trial findings?

I would not change practice based on the findings of this study alone. Treatment cross-over in both arms of the study may obscure the potential benefits of post-MI beta-blocker therapy in patients with preserved EF.

I would certainly have a lower threshold to stop beta blockers in patients who remain stable with preserved LVEF post-MI when seen in follow-up with no other compelling indications for beta-blocker use (i.e., HTN, tachyarrhythmias).